| | Call Details | Cerus Earnings Conference Call (Q3 2009) Thu,
Oct 29, 2009, 4:15 pm Eastern
| | About Cerus
(NasdaqGM:CERS) |
| | Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The companys INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California. |
| More
Info:
Quote
|
Chart
|
News
|
Profile
|
Reports
|
Research
|
SEC
|
Msgs
|
Insider
|
Financials
|
Analyst Ratings |
|